RecruitingNCT07086313
EB-1020 for children and adolescents with ADHD
About this title
Read the official source — NCT07086313Researchers are comparing EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose and placebo to find out how the approaches affect ADHD symptoms in children and adolescents with ADHD.
Medication studyAges 6–17Japan
Understand this study
What is this study about?
Researchers are comparing EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose and placebo to find out how the approaches affect ADHD symptoms in children and adolescents with ADHD.
Who could participate?
This study is for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria apply.
- Listed locations
- SapporoSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 3, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 315
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Japan
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT07086313
- Official title
Show the full official title
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Japan-China Joint Trial to Evaluate the Efficacy and Safety of Two Dose Levels of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention-deficit/Hyperactivity Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Sapporo
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose and placebo to find out how the approaches affect ADHD symptoms in children and adolescents with ADHD.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose and Placebo.
Who can participate?
This study is for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
